Carsten Thiel Sells 3,225 Shares of Alexion Pharmaceuticals Inc. (ALXN) Stock
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) EVP Carsten Thiel sold 3,225 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $128.67, for a total value of $414,960.75. Following the completion of the transaction, the executive vice president now owns 40,354 shares in the company, valued at approximately $5,192,349.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Carsten Thiel also recently made the following trade(s):
- On Tuesday, September 6th, Carsten Thiel sold 1,000 shares of Alexion Pharmaceuticals stock. The shares were sold at an average price of $125.94, for a total value of $125,940.00.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 131.46 on Monday. The firm has a market capitalization of $29.48 billion, a P/E ratio of 330.30 and a beta of 1.08. The stock’s 50 day moving average price is $131.12 and its 200 day moving average price is $136.44. Alexion Pharmaceuticals Inc. has a 12 month low of $110.56 and a 12 month high of $193.45.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The firm had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. During the same quarter last year, the company earned $1.44 earnings per share. The firm’s revenue was up 18.4% on a year-over-year basis. On average, analysts forecast that Alexion Pharmaceuticals Inc. will post $4.65 earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in Alexion Pharmaceuticals during the second quarter worth about $1,056,000. Kentucky Retirement Systems purchased a new stake in Alexion Pharmaceuticals during the second quarter worth about $2,224,000. Mason Street Advisors LLC purchased a new stake in Alexion Pharmaceuticals during the second quarter worth about $3,523,000. Cowen Group Inc. boosted its stake in Alexion Pharmaceuticals by 36.4% in the second quarter. Cowen Group Inc. now owns 4,500 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 1,200 shares during the period. Finally, Royal Bank of Canada boosted its stake in Alexion Pharmaceuticals by 6.6% in the second quarter. Royal Bank of Canada now owns 106,145 shares of the biopharmaceutical company’s stock worth $12,393,000 after buying an additional 6,594 shares during the period. Institutional investors own 96.38% of the company’s stock.
A number of research analysts recently weighed in on ALXN shares. Vetr upgraded Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $146.84 target price on the stock in a report on Thursday, August 25th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $185.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, August 16th. Citigroup Inc. upgraded Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $154.00 target price on the stock in a report on Monday, June 27th. Stifel Nicolaus reduced their target price on Alexion Pharmaceuticals from $195.00 to $182.00 and set a “buy” rating on the stock in a report on Friday, July 29th. Finally, Cowen and Company reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 29th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $182.80.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.